Thalia Therapeutics - Posting of Annual Report and Notice of AGM

Thalia Therapeutics

24/06/2026 15:21

RNS Number : 6303J
  
Thalia Therapeutics PLC
  
24 June 2026
  
 


 
24 June 2026
 
Thalia Therapeutics plc
 
("Thalia" or the "Company")
 
Posting of Annual Report and Notice of AGM
 
Thalia Therapeutics plc (AIM: THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease, announces that its Annual Report for the year ended 31 December 2025 and Notice of the Annual General Meeting, including proposals regarding the acquisition of Sanmirna Therapeutics Inc and associated fundraise, will be posted to shareholders later today, and are available on the Company's website at https://investors.thaliatx.com/aim-rule-26
 
The Company's Annual General Meeting will be held at 11.00 a.m. on 17 July 2026 at the offices of Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.
 
- Ends -
 
For more information please contact:
 




Thalia Therapeutics plc
Dr David H Solomon, Chief Executive Officer


 
Via Thalia Investor Hub
https://investors.thaliatx.com/link/eXglky




SP Angel Corporate Finance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke/Josh Ray (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)


Tel: +44 (0)20 3470 0470




Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker/Guy McDougall 


Tel: +44 (0)20 3657 0050




Northstar Communications Limited
Investor relations and Communications
Sarah Hollins
 
Cohesion Bureau
Investor relations and Communications
Mary-Ann Chang


Tel: +44 (0)20 7183 2463
 
 
 
 
Tel: +44 (0)7483 284853
 
 




About Thalia Therapeutics plc
 
Thalia Therapeutics is a clinical-stage biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. With a growing, differentiated pipeline, de-risked by validated therapeutic targets, we aim to treat diseases at the source by silencing or modifying the genes that cause or contribute to them.
 
Our preclinical bispecific siRNA is a potentially long-acting treatment for atherosclerotic cardiovascular disease, which addresses two independent drivers of cardiovascular risk. Our proprietary delivery technology, Nuvec®, offers the potential to overcome the fundamental challenges of RNA delivery, enabling targeted, scalable RNA therapeutics.
 
For further information visit www.thaliatx.com
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NOAAKQBDQBKDCAB